Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2018

Feb 14, 2019

SELL
$0.98 - $1.85 $49,536 - $93,511
-50,547 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$1.76 - $6.38 $88,962 - $322,489
50,547 New
50,547 $89,000

Others Institutions Holding GERN

About GERON CORP


  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $1.59B
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.